

For many children with diabetes, understanding their condition and how to live with it is a great achievement.

At Novo, we recognise all

the effort needed in both teaching and learning about diabetes. That is why we are very happy

That is why we are very happy to announce our 'Keeping Well With Diabetes'

'Keeping Well With Diabetes Children's Award Scheme.

The Scheme will offer your young diabetics certificates and beautifully enamelled bronze, silver and gold badges for attaining increasing levels of understanding of their diabetes.

If you would like to know more about the scheme and how the children attending your clinic can enter, just fill in the form for further details.

NOVO



CHILDREN'S AWARD SCHEME

Please send me further details of the 'Keeping Well With Diabetes' Children's Award Scheme

Name

Position

Hospital

(please print)

Novo Laboratories Limited, Ringway House, Bell Road, Daneshill East, Basingstoke, Hampshire RG24 0QN.

whatever m worries about, it won't be his asthma.

Regular Intal therapy can give real protection from asthmatic attacks, minimising both incidence and severity.1

With reduced anxiety, there is less need to resort to symptomatic medication such as bronchodilators? or oral corticosteroids?

Current investigations suggest that these improvements are accompanied by a reduction of cellular infiltration in bronchial mucus. Which indicates that Intal therapy may have a beneficial effect on the underlying pathology of asthma.

Because the Intal routine can be integrated unobtrusively into the day's normal activities, the asthmatic child can get on with the real business of growing up.

> He'll be more at ease with his condition. And so will his parents, teachers and friends.

References:

1. Bernstein, L. et al., J.Allergy Clin.Immunol., (1972), 50, 4, 235-245. Rubin, A. E., Alroy, G. & Spitzer, S., Curr.Med. Res. Opin., (1983), 8, 553.
 Toogood, J. H. et al., J. Allergy Clin. Immunol., (1973), 52, 6, 334-345. 4. Diaz, P. et al., Thorax. (1983), 38, 9, 702-703.

Presentation Intal and Intal Compound Spincaps® both contain 20mg Sodium Cromoglycate B.P. Isoprenaline Sulphate (0.1mg) is included in Intal Compound Spincaps. The powder from Spincaps is inhaled using the Spinhaler® or Halermatic® which work by the patient's inspiratory effort. The Intal Inhaler is a metered dose pressurised aerosol delivering 200 inhalations of 1.0mg Sodium Cromoglycate. Intal Nebuliser Solution is presented in ampoules each containing 20mg Sodium Cromoglycate in 2ml sterile queous solution. Indication Preventive treatment of bronchial asthma, including the prevention of exercise-induced asthma. Dosage and Administration Adults and children: the normal dose is one Spincap (Intal or Intal Compound) two puffs of Inhaler or one ampoule of Nebuliser Solution to be inhaled four times daily. Intal Nebuliser Solution is administered from a suitable power-operated nebuliser. Since Intal therapy is preventive it is important that the patient is instructed to maintain regular dosage as distinct from intermittent use to relieve symptons. Side effects With the powder formulations of Intal, irritation of the throat and trachea may occur in patients sensitive to the inhalation of dry powder. Although it has not been reported for the Inhaler or Nebuliser Solution, rare cases of severe bronchospasm have occurred following the administration of Intal Spincaps using a Spinhaler. Precautions For Intal Compound the precautions normally applying to isoprenaline should be observed. Withdrawal of therapy This should be done progressively over one week. Symptoms may recur. Any previous steroid therapy should be reinstated prior to the withdrawal of Intal. PLOUI SEASON UNET UNIX WEEK. SYMIDIUM IS MBY RECUI. ANY previous steroid merapy should be reinstated prior to the withdrawal of Intal.

Basic NHS Cost and Product Licence Number Intal (per 100 Spincaps) £10.07 PL0113/5022. Intal Compound (per 100 Spincaps) £10.95 PL0113/0080. Nebuliser Solution (per 48 ampoules) £8.20

PL0113/0088. Fisons pic—Pharmaceutical Division, Loughborough, Leicestershire LE11 0BB. **Registered Trade Mark ©Fisons pic

Pharmaceuticals 5 4 1



Intal[®] for firm control of asthma



FCREWAY. Entertail in the second of the sec

For the first time.

The bactericidal power of aminoglycosides and exceptional antipseudomonal activity from an extended spectrum cephalosporin.

Hospital antibiotics created in Britain by

Glaxo

A TRULY REMARKABLE CEPHALOSPORIN

ceftazidime

PRESCRIBING INFORMATION

Fortum for Injection is supplied in vials containing 500mg, 1g and 2g ceftazidime (as pentahydrate) with sodium carbonate.

Fortum is a bactericidal cephalosporin antibiotic which is resistant to most beta-lactamases and is active against a wide range of Gram-positive and Gram-negative bacteria.

It is indicated for the treatment of single infections and for mixed infections caused by two or more susceptible organisms. Fortum, because of its broad antibacterial spectrum, may be used alone as first choice drug, pending sensitivity test results.

Dosage and administration
The usual adult dosage is in the range 1g to 6g i.m. or i.v. per day (see Data Sheet for details).

Contra-indication

Fortum is contra-indicated in patients with known hypersensitivity to cephalosporin antibiotics.

Precautions
Cephalosporins may, in general, be given safely to patients who are hypersensitive to penicillins. Care is indicated in patients who have experienced an anaphylactic reaction to penicillin.

Cephalosporin antibiotics at high dosage should be given with caution to patients receiving concurrent treatment with nephrotoxic drugs. Clinical experience with Fortum has shown that this is not likely to be a problem at the recommended dose levels. Reduce dosage when renal function is impaired (see Data Sheet).

As with all drugs, Fortum should be administered with caution during the early months of pregnancy and in early infancy. Fortum is excreted in human milk in low concentrations.

Fortum does not interfere with enzyme-based tests for glycosuria. Slight interference with copper reduction methods may be observed. Fortum does not interfere in the alkaline picrate assay for creatinine. Fortum and aminoglycosides should not be mixed in the same giving set or syringe.

As with other broad spectrum antibiotics, prolonged use of Fortum may result in the overgrowth of non-susceptible organisms (e.g., Candida, Enterococci) which may require interruption of treatment or adoption of appropriate measures.

Side effects

Fortum is generally well tolerated with only infrequent adverse reactions, e.g., pain and/or inflammation after i.m. administration and phlebitis and/or thrombophlebitis after i.v. administration, rashes, fever pruritis, gastro-intestinal disturbances, headache, dizziness, paraesthesiae and bad taste. Transient changes in laboratory values may occur including; eosinophilia, a positive Coombs' test, thrombocytosis and clicit tries in hongitic enzymes. and slight rises in hepatic enzymes

Basic NHS cost (exclusive of VAT)
The basic NHS cost of Fortum is £9.90 per gram.
Available in packs of; 5 x 500mg, 5 x 1g and 5 x 2g vials and an infusion pack of 5 x 2g vials.

Product Licence numbers 500mg: 0004/0292 1g: 0004/0293 2g: 0004/0294

Further information is available on request from:

Glaxo

Glaxo Laboratories Limited, Greenford, Middlesex UB6 OHE

Fortum is a Glavo trade mark

This Publication is available in Microform.



University Microfilms International

ion
(name of publication)

300 North Zeeb Road Dept. P.R. Ann Arbor, Mi. 48106

Hospital antibiotics created in Britain by



European Journal of Pediatrics

Incorporating

ACTA PAEDIATRICA BELGICA

Volume 141 Number 4 February 1984

Last issue of this volume

The pioneers of pediatric medicine 191

Review

R. C. A. Sengers, A. M. Stadhouders, J. M. F. Trijbels: Mitochondrial myopathies. Clinical, morphological and biochemical aspects 192

Original investigations

- A. Niederwieser, N. Blau, M. Wang, P. Joller, M. Atarés, J. Cardesa-Garcia: GTP cyclohydrolase I deficiency, a new enzyme defect causing hyperphenylalaninemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia 208
- B. N. Harding, J. V. Leonard, M. Erdohazi: Ornithine carbamoyl transferase deficiency: A neuropathological study 215
- J. M. van der Klei-van Moorsel, A. C. Douwes, J. P. van Oeveren: New principle for estimation of hydrogen in expired air 221
- B. Schmidt, U. Wais, W. Pringsheim, W. Künzer: Plasma elimination of antithrombin III (heparin cofactor activity) is accelerated in term newborn infants 225
- P. Lebecque, G. Bosi, J. Lintermans, M. Stijns, J. Germanes, Ch. H. Chalant, A. Vliers: Myxomatous degeneration of the mitral valve in a child with Turner syndrome and partial anomalous pulmonary venous return 228

- M. Eiken, J. Prag, K. E. Petersen, H. J. Kaufmann: A new familial skeletal dysplasia with severely retarded ossification and abnormal modeling of bones especially of the epiphyses, the hands, and feet 231
- M. Sagy, M. Aladjem, A. Shem-Tov, A. Eshkol, S. Orda, J. Hegesh, H. Boichis: The renal effects of radiocontrast administration during cardioangiography in two different groups with congenital heart disease 236
- I. Goto, T. Yoshimura, Y. Kuroiwa: Growth hormone studies in lysinuric protein intolerance 240
- J. Sjövall, A. Fogh, B. Huitfeldt, G. Karlsson, O. Nylén: Methods for evaluating the taste of paediatric formulations in children: A comparison between the facial hedonic method and the patients' own spontaneous verbal judgement 243

Case reports

- R. de Groot, C. E. Essed, J. L. J. Gaillard, J. W. Mettau, V. H. Villeneuve: Primary restrictive foramen ovale 248
- P. Balestrazzi, M. G. Mattei, M. A. Baeteman, J. F. Mattei, F. Giraud: Bilateral retinoblastoma with de novo constitutional balanced translocation t(2;9) (q11;p11) 250
- D. C. Aronson, H. S. A. Heymans, R. P. G. M. Bijimer: Cor pulmonale and acute liver necrosis, due to upper airway obstruction as part of pycnodysostosis 251
- J. Passwell, T. Rosenthal, H. Boichis, Z. Barzilai, P. A. Vardy, Z. Rubinstein, E. Cohen: Transient renovascular hypertension in childhood 254

Subscription information: Volumes 142 and 143 (4 issues each) will appear in 1984. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: Approx. US \$ 336.00 including carriage charges. Subscriptions are entered with prepayment only. Orders should be addressed to: Springer-Verlag New York Inc., Service Center Secaucus, 44 Hartz Way, Secaucus, NJ 07094, USA, Tell. (201) 348-4033, Telex 00 23-125 994.

All other countries. Annual subscription rate: DM 820.00 plus carriage charges. Airmail delivery on request only. For Japan, carriage charges. (Surface Airmail Lifted) are DM 71.50; for India DM 43.40. Single issue price: DM 123.00 plus carriage charges. Orders can either be placed with your bookdealer or sent directly to: Springer-Verlag, Heidelberger Platz 3, D-1000 Berlin 33, Tel. (0) 30 / 82 07-1, Telex 01-83 319.



Springer International



In 1982 a new form of insulin was launched on the U.K. market.

Humulin. It's outstandingly pure. ¹ And it's a less immunogenic form of insulin than that which comes from the pancreas of pigs and cattle. ²

Hence it produces fewer antibodies.² Basically, Humulin uses genetic engineering and the techniques of recombinant DNA technology as the method of manufacture.

Which means it can be produced economically and in large quantities for years to come.

In spite of this, however, many young diabetics like Matthew are still being prescribed purified pork insulin.

Why? We don't really know. But what we do know is that the future is likely to see all patients on human insulin.

So why shouldn't they be prescribed it now? After all, it's available in a variety of formulations to suit differing needs.

Humulin

Human Insulin (crb)
THE HUMAN WAY TO TREAT DIABETES

Humulin

Human Insulin (crb)

'HUMULIN'S ▼ 'HUMULIN'I ▼ 'HUMULIN' Zn ▼ Human insulin (crb) Presentation: Humulin S: A sterile, aqueous solution of human insulin (crb), 40, 80 and 100 IU/ml. Humulin I: A sterile suspension of isophane human insulin (crb), 40,80 and 100 IU/ml. Humulin Zn: A sterile suspension of crystalline human insulin (crb), 100 IU/ml. Uses: For the treatment of insulindependent diabetics. Dosage and Administration: The dosage should be determined by the physician, according to the requirements of the patient. Humulin S may be administered by subcutaneous, intramuscular or intravenous injection. Humulin I and Humulin Zn should be administered by subcutaneous or intramuscular injection only. Humulin S may be administered in combination with Humulin I or Humulin Zn as required. Humulin I and Zn: Rotate vial in palm of hands before use to re-suspend. Mixing of insulins: The shorter-acting insulin should be drawn into the syringe first, to prevent contamination of the vial by the longer-acting preparation. It is advisable to inject immediately after mixing. Contra-indications, Warnings, etc. Contra-indications: Hypoglycaemia. Under no circumstances should Humulin I or Humulin Zn be given intravenously. Precautions: Usage in <u>pregnancy</u>: Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. Transferring from other insulins: A small number of patients transferring from insulins of animal origin may require a reduced dosage, especially if they are very tightly controlled and bordering on hypoglycaemia. The risk of hypoglycaemia can be considered minimal if the daily dosage is less than 40 IU. Insulin-resistant patients receiving more than 100 IU daily should be referred to hospital for transfer. <u>Side</u> effects: Lipodystrophy, insulin resistance and hyper-Package Quantities: 10ml glass vials in packs of 5.

Price: Humulin S: 40 IU/ml £2.70, 80 IU/ml £5.40, 100 IU/ml £6.44. Humulin I: 40 IU/ml £2.70, 80 IU/ml £2.70, 80 IU/ml £5.40, 100 IU/ml £6.44. Humulin I: 40 IU/ml £2.70, 80 IU/ml £5.40, 100 IU/ml £6.44. Humulin Zn: 100 IU/ml £6.44

Product Licence Numbers:

Humulin S 40 IU/ml 0006/0163
Humulin S 80 IU/ml 0006/0164
Humulin S 100 IU/ml 0006/0165
Humulin I 40 IU/ml 0006/0166
Humulin I 80 IU/ml 0006/0167
Humulin I 100 IU/ml 0006/0167
Humulin I 100 IU/ml 0006/0179.
Date of preparation: December 1983. Full Prescribing Information Available From: Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire, RG21 2XA. Or from: Eli Lilly and Company Limited, 5
Percy Place, Dublin 4. Telephone: 680 179. 'HUMULIN' is a trade mark. HU68 Dec '83
I. Johnson I. S., Diabetes Care 1982, Vol. 5, Suppl. 2, 4-12. 2. Fineberg, S. E. et al (Indianapolis), Diabetes May 1983, 32, Suppl. 1,3A.



Just published

NEW DRUGS

In the past few years the number of important new drugs and our understanding of pharmacology have continued to increase. Reliable and unbiased information on the therapeutic use of these agents is, however, not always readily available. Articles recently published in the BM7 on entirely new groups of drugs – H₂ receptor antagonists, calcium antagonists, captopril – and on new members of groups of drugs already available beta-blockers, tranquillisers, hypnotics, diuretics – fill this gap and are now collected together in book form. Busy practitioners will find that this comprehensive review allows them to make a more rational choice of treatment.

Price: Inland £6.50; Overseas £7.50/USA\$13.00 (Inland £6.00; Overseas £7.00/USA\$12.00 to BMA members) including postage, by air overseas

Payment must be enclosed with order

Order your copy now From: The Publisher British Medical Journal BMA House Tavistock Square London WC1H 9JR or any leading bookseller

Monatsschrift Kinder- Organ der Deutschen Gesellschaft für Kinderheilkunde heilkunde

132. Band Heft 3 März 1984

Springer-Verlag Berlin Heidelberg New York Tokyo

	Thema des Monats	This Month's Topic	
	Proteinurie	Proteinuria	13
J. H. H. Ehrich, H. G. Foellmer, F. Krull, H. J. Winnecken, U. Wurster	Aussagen, Fehlerquellen und Grenzen der Protein- diagnostik im Urin. I. Diagnostische Methoden	Diagnosing Proteinuria. I. Methods of Analysis	13
J. H. H. Ehrich, H. G. Foellmer, F. Krull, H. J. Winnecken, U. Wurster	Aussagen, Fehlerquellen und Grenzen der Protein- diagnostik im Urin. II. Normalwerte und Klassi- fikation der pathologischen Proteinurien	Diagnosing Proteinuria. II. Physiological and Pathological Types	14
	Pädiatrie aktuell	Trends in Paediatrics	15
	Was hat das Kind?	What's Wrong with the Child?	15
	Aus Klinik und Forschung Originalien	Clinic and Research Originals	
D. E. Müller-Wiefel, A. Mohr, E. Willich	Faltenbildungen im proximalen Ureter	Mucosal Membranes of the Proximal Ureter	15
H. Böhles, U. Brandl, G. Schott, K. Stehr	Klinische und chemische Faktoren der Nierensteinbildung im Kindesalter	Clinical and Chemical Parameters of Kidney Stone Formation in Pediatrics	15
F. Manz, P. Vecsei, H. Wesch	Renale Säureausscheidung und renale Molenlast bei gesunden Kindern und Erwachsenen	Renal Net-Acid-Excretion and Osmolar Load in Normal Children and Adults	16
C. Simon, A. Bahr, G. Kreller, D. Kiosz	Untersuchungen über eine optimale Blutkultur- technik	Optimizing Technique for Blood Cultures	16
V. Ch. Hecker, A. M. Holschneider, K. Schimmel	Behandlungsergebnisse nach der Durchzugs- operation und nach kontinenzverbessernden Operationen bei hoher Anal- und Rektumatresie	Results of Pull-Through-Procedures and Continence-Improving Operations for High Ano- Rectal Atresia	17
	Der interessante Fall	The Interesting Case	
M. Rister, W. Rudolph, K. Lemmen, W. Konen	Das Torsten-Sjögren-Syndrom	The Torsten-Sjögren-Syndrome	18
H. B. v. Stockhausen, H. G. Hansen, D. Mönkemeier, A. Mührer	Riesenhämangiom der Plazenta als Ursache einer lebensbedrohlichen Neugeborenenanämie mit Hydrops congenitum	Gigant Haemangioma of the Placenta Causing Dangerous Anaemia of a Newborn with Hydrops Congenitum	18
U. Querfeld, H. Sandbrink, H. C. Oppermann	latrogener Hydrothorax bei einem Frühgeborenen und seine Behandlung	latrogenic Hydrothorax and Its Treatment in a Premature Infant	18
	Wußten Sie schon?	Do You Know?	
	Aus der Klinik – für die Klinik	Clinical Tips for Clinicians	
D. W. Roloff, S. M. Donn, J. W. Keyes, Jr.	Die lumbale Radioisotopen-Zisternographie bei Frühgeborenen	Lumbar Cisternography with Radioisotopes in Prematures	18
	Auflösung und Kommentar der Fragen "Was hat das Kind?"	Solution and Commentary of the Questions ,,What's Wrong with the Child?"	18
	Briefe an die Redaktion – Diskussionen	Letters to the Editor	19
	Neue Bücher	New Books	19
	Tagesgeschichte, Personalia	News of the Day, Personal News	19
	Tagungskalender	Forthcoming Meetings	19
	Für die Dokumentation	Documentation	A 6
	The second secon		

Indexed in Current Contents

Monatsschr Kinderheilkd (1984) 132, 3

Contents

Editorial

Announcement

B. S. Rosenstein and J. M. Ducore (Dallas, Texas)

Enhancement by Bilirubin of DNA Damage Induced in Human Cells Exposed to Phototherapy Light Bilirubin appears to act as a photosensitising agent that enhances the level of DNA damage in cells exposed to phototherapy light.

Cerebral Blood Flow and Experimental Intraventricular Hemorrage

J. GODDARD-FINEGOLD AND L. H. MICHAEL (Houston, Texas)

Cerebral blood flows increase significantly in the newborn beagle puppy during hypovolemic hypotension of short duration and immediately after volume reinfusion. These insults produce intraventricular hemorrhages in this neonatal animal.

Prostaglandin Biosynthetic Activities of Isolated Fetal Lamb Ductus Arteriosus, Other Blood Vessels, and Lung Tissue

R. A. SKIDGEL, W. F. FRIEDMAN, AND M. P. PRINTZ (La Jolla, California and Los Angeles, California)

Among several conclusions derived from this study, the authors report that the isolated ductus arteriosus synthesizes predominantly PGI2 with minimal evidence of PGE, biosynthetic capacity.

Studies of Pulmonary Prostaglandin Biosynthetic and Catabolic Enzymes as Factors in Ductus Arteriosus Patency and Closure. Evidence for a Shift in Products with Gestational Age

M. P. PRINTZ, R. A. SKIDGEL, AND W. F. FRIEDMAN (La Jolla, California and Los Angeles, California)

The authors suggest that there is a "balanced mechanism" which regulates the ductus arteriosus and includes both locally generated and hormonally acting prostaglandins and prostanoids.

The Effects of Mendelian Mutation on Renal Sulfate and Phosphate Transport in Man and Mouse D. E. C. COLE AND R. SCRIVER (Montreal, Quebec, Canada and

Halifax, Nova Scotia, Canada)

These findings provide further evidence that sulfate and phosphate anions are conserved from renal filtrate by independent processes in the bush-border membrane of mammalian kidney.

Complete Deficiency of Adenine Phosphoribosyltransferase: a Report of Three Cases and Immunologic and Phagocytic Investigations

T. KISHI, K. KIDANI, Y. KOMAZAWA, N. SAKURA, R. MATSUURA, M. KOBAY-ASHI, A. TANABE, S. HYODO, E. KIT-TAKA, T. SAKANA, Y. TANAKA, Y. KOBAYASHI, T. NAKAMOTO, H. NAK-ATSU, H. MORIYAMA, M. HAYASHI, H. NIHIRA, AND T. USUI (Hiroshima, Japan and Onomichi, Japan)

The authors report levels of adenine phosphoribosyltransferase in red blood cells, peripheral mononuclear cells, and polymorphonuclear leukocytes from normal controls and two families with adenine phosphoribosyltransferase.

Concentrations of α₁-Proteinase Inhibitor and α₂-Macroglobulin in Serum and Lung Secretions of Intubated Infants

M. C. BRUCE, R. J. MARTIN, AND T. F. BOAT (Cleveland, Ohio)

This study investigates concentrations of α_1PI and α_2M , proteinase inhibitors, in serum and lung secretions as a function of both gestational and postnatal age.

Developmental Aspects of the Renal Response to Hemorrhage during Fetal Life R. A. GOMEZ, J. G. MEERNIK, W. D.

KUEHL, AND J. E. ROBILLARD (IOWA City, Iowa)

The fetal renal response to blood volume depletion tends to be more pronounced as

gestation advances and seems to depend, at least partially, on the degree of development of the neuro-humoral responses.


Liquid Ventilation: Effects on Pulmonary Function in Distressed Meconium-Stained Lambs

T. H. SHAFFER, C. A. LOWE, V. K. BHUTANI, AND P. R. DOUGLAS (Philadelphia, Pennsylvania)

Liquid ventilation provides a means to improve oxygenation and lung compliance in newborn lambs with meconium-staining and asphyxia.

Developmental Changes in Action Potential Duration, Refractoriness, and Conduction in the Canine Ventricular Conduction System

W. J. UNTEREKER, P. DANILO, JR., AND M. R. Rosen (New York, New York) The authors report significant changes with age between the relationship of action potential duration and anatomic location in the specialized conducting system.



`CORDEX'

SELF-BINDING CASES

for easy and instant reference

Made to hold one volume (12 issues) of your ARCHIVES OF DISEASE IN CHILDHOOD. Each case is handsomely bound with a colour to complement the journal. Spring nylon cords, to carry the journals, slide freely along the spine of the binder. The name of the journal is gold-blocked on the spine. Date labels are also provided.

Price: Inland £4.00; Overseas US\$12.00 including postage (air mail overseas) and packing

ORDER NOW

From: The Subscription Manager,
ARCHIVES OF DISEASE IN CHILDHOOD
BMA House, Tavistock Square, London WC1H 9JR



Tegretol® making epilepsy

easier to live with

Tegretol*
Indications Epilepsy (generalised tonic-clonic and partial seizures), trigeminal neuralgia <u>Dosage in epilepsy</u> Use a gradually increasing dosage scheme, adjusting to patient's needs. Adults: 100-200 mg one or twice daily, increasing slowly up to 800-1200 mg daily; in some cases 1,600 mg daily may be necessary. Children: up to 1 year old, 100-200 mg daily; aged 1-5 years, 200-400 mg daily; aged 5-10 years, 400-600 mg daily; aged 1-5 years, 600-1,000 mg daily; nay be necessary. Children: up to 1 year old, 100-200 mg daily; aged 1-5 years, 200-400 mg daily; aged 1-5 years, 200-400 mg daily; aged 1-5 years, 400-600 mg daily; aged 1-5 ye